EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, REGN: Regeneron Pharmaceuticals

27 Oct 25 12:41
LAST:

580.3

CHANGE:
 2.17		OPEN:
582.1		HIGH:
586.1		ASK:
311.4		VOLUME:
171.5K
CHG(%):
0.37		PREV:
578.1		LOW:
575.9		BID:
25.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Oct 25582.1586.1575.9580.3171.5K
24 Oct 25579.7582.7576.2578.0875.4K
23 Oct 25579.7584.0572.7575.7779.1K
22 Oct 25580.2588.7578.6584.7691.2K
21 Oct 25574.6582.4572.8579.3651.7K
20 Oct 25579.4582.6574.2576.8639.1K
17 Oct 25570.4579.0566.1578.1745.7K
16 Oct 25583.0589.1564.0569.2842.2K
15 Oct 25575.0584.9569.0576.4927.7K
14 Oct 25556.9576.2553.9572.61.01M

COMPANY PROFILE

Name:Regeneron Pharmaceuticals
About:Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Sector:Healthcare
Industry:Biotechnology
Address:777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Website:https://www.regeneron.com
CUSIP:75886F107
CIK:0000872589
ISIN:US75886F1075
FIGI:BBG000C734W3
LEI:549300RCBFWIRX3HYQ56

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:14.20 
Forward P/E:12.44 
EPS Ratio:39.70 
DivYield:0.00 
Div/Share:1.76 
Price to Book:1.96 
Price to Sales:4.47 
EBITDA:4.467B 
Shares:104.17M 
Market Cap:60.445B 

TECHNICAL INDICATORS

MA5:579.810.1%
MA10:577.210.5%
MA20:577.960.4%
MA50:576.330.7%
MA100:559.783.7%
MA200:595.662.7%
STO9:61.05
STO14:49.92
RSI14:49.01
WPR14:-12.64 
MTM14:17.47
ROC14:0.03 
ATR:16.71 
Week High:588.711.5%
Week Low:572.751.3%
Month High:618.016.5%
Month Low:541.002.7%
Year High:943.2762.6%
Year Low:476.4921.8%
Volatility:13.58 

RECENT DIVIDENDS

Date Amount
18 Aug 2025$0.88
20 May 2025$0.88
20 Feb 2025$0.88